INTRODUCTIONNewer generation drug‐eluting stents (DES) have been developed. These stents feature thinner struts and biocompatible or biodegradable polymers that release eluted drug at lower dosages, resulting in a remarkable reduction in the risk of death, stent thrombosis (ST), or myocardial infarction (MI), as well as a lower risk of repeat revascularization . The biodegradable‐polymer sirolimus‐eluting stent (BP‐SES) (Tivoli, Essen Technology, Beijing, China) represents a further iteration of DES technology by combining a biodegradable polymer with cobalt–chromium (CoCr) platform. In the prior reported one‐year result of I‐LOVE‐IT 2 (Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization) trial, the BP‐SES was noninferior to the durable‐polymer sirolimus‐eluting stent (DP‐SES) (Firebird2, Microport Medical, Shanghai, China) in the primary composite safety and efficacy endpoint of target‐lesion failure (TLF) at 12 months . Nevertheless, long‐term data comparing the BP‐DES versus the DP‐DES are scarce. The purpose of this study was to report the long‐term clinical outcomes of patients included in the I‐LOVE‐IT 2 trial over a 3‐year follow‐up period.MATERIALS AND METHODSStudy Design and PatientsThe I‐LOVE‐IT 2 trial (NCT01681381) was a prospective, multicenter, randomized, assessor‐blinded, noninferiority study comparing the BP‐SES with the DP‐SES. Between October 2012 and
Catheterization and Cardiovascular Interventions – Wiley
Published: Jan 15, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera